|  |  | 

India Top Headlines

Cases in India are falling but deaths are high; CFR rises in May | India News


Cases in India are falling but deaths are high; CFR rises in May | India News

The CFR in the last week has risen to 1.1%, up from 0.7% during April.

NEW DELHI: India reported 3.43,122 new cases and about 4,000 deaths on Thursday. While the seven-day average of daily cases has steadily fallen from a peak of 3.91 lakh on Saturday to 3.64 lakh, indicating that the peak of the second wave may have been reached, the average daily deaths have risen further. beyond the 4,000 to 4,039 mark, reports Amit Bhattacharya. The CFR in the last week it has risen to 1.1%, compared to 0.7% in April.
Starting this month, 50% of all doses manufactured in a month and approved by the Central Drug Laboratory for the release will be acquired by the Center. Of the remaining 50%, half will be for state acquisitions and the other half for the private sector.
What will the Center do with the 50% it buys?
This will be allocated between states. The Center has said that the allocation will be based on criteria such as the burden of active cases in a state and its vaccination performance (percentage of the doses that have been administered that it has consumed). A negative criterion will be the degree of waste of doses delivered to a state – the greater the waste, the more it will count against the state in future supplies. The doses purchased by the Center and allocated to the states will be used to vaccinate people 45 years of age and older, not the population 18 to 44 years of age.
Can a state buy as much as it wants within the 50% quota for states?
No. This quota is allocated among states based on their population ages 18-44. The larger the population of this age group in a state, the greater its share.
Is there a similar state allocation for the private sector?
No. Subject to the limit on the total doses that the private sector can buy, private buyers are left with the task of closing deals with vaccine manufacturers. This has raised concerns that much of this share, 25% of total production, can be used in the largest cities where private hospital chains are concentrated.
Do states have to use the doses they buy directly from manufacturers only for the 18-44 age group?
The policy does not make such a stipulation. In fact, several states have stated that, given supply constraints, they will prioritize providing second doses to the population over 45 and may use part of what they purchase for this purpose.
At what price do several buyers receive the vaccines?
The Center continues to purchase the vaccines at Rs 150 per dose, as before. Serum Institute of India, that makes Covishield, has stated that it will be sold to states at Rs 300 per dose and to the private sector at Rs 600 per dose. Bharat Biotech, the manufacturer of Covaxin, has said that it will be sold to states at 400 rupees per dose and to the private sector at 1200 rupees per dose. Therefore, states will pay at least twice as much as the Center for the same vaccines.
Has the price at which private hospitals supply the vaccine been set?
No. Whereas in the previous policy, there was a fixed price of Rs 250 per dose in private hospitals, under the current policy there is no limit on the price they can charge regardless of the age of the recipient.


Times of India